We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Exosome Diagnostics to Validate Life Technologies Platform for Biofluid Isolation Kits

By LabMedica International staff writers
Posted on 19 Jun 2012
Exosome Diagnostics (New York, NY, USA) has reached an agreement with Life Technologies (Carlsbad, CA, USA) to use the Applied Biosystems (ABI) 7500 fast Dx real-time polymerase chain reaction (PCR) instrument for the company’s exosome biofluid in vitro diagnostics oncology program. Exosome Diagnostics plans to validate the ABI instrument platform with exosome biofluid RNA isolation technology kits in multicenter clinical trials in brain and prostate cancer beginning in 2012.

The ABI 7500 fast Dx real-time PCR instrument is one of the most widely distributed PCR platforms in laboratories worldwide and is cleared by the Food and Drug Administration (FDA; Silver Spring, MD, USA).

Exosome Diagnostics is developing a series of urine and blood-based molecular diagnostic tests for use in cancer detection and monitoring. The company's technology can isolate a highly pure, stable preparation of ribonucleic acids from biofluids for analysis on existing analytical platforms such as real time quantitative PCR (qPCR) and next-generation sequencing. The company is partnering with various manufacturing groups to provide branded, original equipment manufacturer (OEM) in vitro diagnostic solutions for regulatory approval and use in the its good laboratory practice (GLP) clinical laboratory improvements amendments (CLIA)-certified laboratory.

"This agreement with Life Technologies continues our pursuit of best-in-class partnerships that include the Prostate Cancer Foundation, Accelerate Brain Cancer Cure and the broad group of leading clinical investigators now collaborating on exosome technology," said James McCullough, CEO of Exosome Diagnostics. "Life Technologies is leading the way in personalized medicine and provides us with the type of customer service and robust technology that are prerequisites to the successful launch of innovative molecular diagnostics."

Related Links:

Exosome Diagnostics
Life Technologies
Food and Drug Administration




Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Automated Biochemical Analyzer
iBC 900

Latest Industry News

Quanterix Completes Acquisition of Akoya Biosciences
19 Jun 2012  |   Industry

Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
19 Jun 2012  |   Industry

AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
19 Jun 2012  |   Industry



PURITAN MEDICAL